GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Effective Interest Rate on Debt %

Cadence Pharmaceuticals, (FRA:QEW) Effective Interest Rate on Debt % : 15.32% (As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Cadence Pharmaceuticals,'s annualized positive value of Interest Expense for the quarter that ended in Dec. 2013 was €3.31 Mil. Cadence Pharmaceuticals,'s average total debt for the quarter that ended in Dec. 2013 was €21.62 Mil. Therefore, Cadence Pharmaceuticals,'s annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2013 was 15.32%.


Cadence Pharmaceuticals, Effective Interest Rate on Debt % Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Effective Interest Rate on Debt % Chart

Cadence Pharmaceuticals, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.67 12.42 15.46 15.49 15.04

Cadence Pharmaceuticals, Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.30 15.33 15.18 15.30 15.32

Competitive Comparison of Cadence Pharmaceuticals,'s Effective Interest Rate on Debt %

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadence Pharmaceuticals,'s Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Effective Interest Rate on Debt % falls into.



Cadence Pharmaceuticals, Effective Interest Rate on Debt % Calculation

Cadence Pharmaceuticals,'s annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2013 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2012 )+Total Debt  (A: Dec. 2013 ))/ count )
=-1  *  -3.261/( (21.959+21.4)/ 2 )
=-1  *  -3.261/21.6795
=15.04 %

where

Total Debt  (A: Dec. 2012 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=21.959 + 0
=21.959

Total Debt  (A: Dec. 2013 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=13.533 + 7.867
=21.4

Cadence Pharmaceuticals,'s annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2013 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2013 )+Total Debt  (Q: Dec. 2013 ))/ count )
=-1  *  -3.312/( (21.833+21.4)/ 2 )
=-1  *  -3.312/21.6165
=15.32 %

where

Total Debt  (Q: Sep. 2013 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=15.896 + 5.937
=21.833

Total Debt  (Q: Dec. 2013 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=13.533 + 7.867
=21.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2013) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Cadence Pharmaceuticals,  (FRA:QEW) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Cadence Pharmaceuticals, Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, (FRA:QEW) Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines